Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 181

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 181
---
 par value of $0.00001 per share. As of December 31, 2024 and 2023, there were 51,935,134 and 51,445,862 shares of common stock issued and outstanding, respectively. Common stockholders are entitled to receive dividends if and when declared by the board of directors subject to the rights of any preferred stockholders. As of December 31, 2024, no dividends on common stock had been declared by the Company.As of December 31, 2024 and 2023, the Company had reserved shares of common stock for issuance as follows: 

        December 31,

        2024

        2023

        Options issued and outstanding

        8,653,913

        6,973,464

        Shares available for future stock option and RSU grants

        5,321,104

        4,474,411

        Shares available for employee stock purchase plan

        1,408,321

        1,056,832

        Total

        15,383,338

        12,504,707

      ATM ProgramOn October 4, 2021, the Company entered into an at-the-market offering program (the “ATM Program”) pursuant to which, the Company may offer and sell shares of its common stock having aggregate gross sales proceeds of up to $150.0 million from time to time. As of December 31, 2024, the Company had approximately $113.8 million remaining in gross proceeds available for future issuances of common stock under the ATM Program.

8.   Stock Plan2020 Equity Incentive PlanThe 2020 Equity Incentive Plan (the “2020 Plan”) was approved by the Company’s  board of directors on September 24, 2020.  The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The number of shares of common stock initially reserved for issuance under the 2020 Plan was 4,406,374, which shall be increased, upon approval by the Company’s  board of directors, on January 1, 2021 and each January 1 thereafter, in an amount equal to the least of (i) 4,406,374 shares of